Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VG111
- Development stage
- Phase 3
- Lead developer
- Post Graduate Institute of Medical Education and Research
- Modality
- Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical
01
Overview
VG111 is a patented, natural product-based topical formulation developed by researchers at the Postgraduate Institute of Medical Education and Research (PGIMER) in Chandigarh, India, in collaboration with the Institute of Nano Science and Technology (INST) in Mohali. Comprising herbal ingredients described in the Ayurvedic Pharmacopeia of India, VG111 is designed to promote wound healing and provide broad-spectrum antimicrobial activity without inducing cytotoxicity. It has been formulated into a sodium carboxymethylcellulose (NaCMC)-croscarmellose hydrogel matrix to optimize moisture retention and sustained topical delivery for burn wounds and other complex chronic wounds. VG111 exhibits potent antimicrobial and biofilm-disrupting properties against key pathogens, including methicillin-resistant *Staphylococcus aureus* (MRSA), colistin-resistant *Escherichia coli*, and *Acinetobacter baumannii*. It also demonstrates immunomodulatory effects by reducing inflammatory cytokines (such as IL-6 and TNF-alpha) and promoting fibroblast and keratinocyte proliferation.
- Other names
- AE-VG111AE-VG-111AE-VG 111
02
Targets
IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on VG111.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VG111.